Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Am J Transplant. 2015 Nov 9;16(2):672–678. doi: 10.1111/ajt.13483

Figure 2. In vivo B cell depletion using 5D2 IgG2a anti-CD20 mAbs.

Figure 2

OT1 mice were injected with 5D2 IgG2a anti-CD20 antibody (250 µg given intraperitoneally). The percentages of B cells among total lymphocytes were evaluated at different time points in the peripheral blood and bone marrow (BM) (A) as well as lymph nodes (LN) and spleen (B) of anti-CD20 mAb-treated (solid symbols) or control untreated (open symbols) mice via fluorescence activated cell sorter staining with an anti-CD19 antibody. The percentages of CD19+ B cells among lymphocytes of control untreated OT1 mice were as follows: bone marrow: 52%, peripheral blood: 48%, lymph nodes: 28%, and spleen: 46%. The results are representative of three to four mice tested at each time point.